Inactive Instrument

Nissui Pharmaceutical Co., Ltd.

Equities

4550

JP3678100003

Announcement: Transition of distribution in Europe, Turkey and Africa

October 30, 2021 at 10:02 pm EDT

News Release

To: All Concerned

October 1, 2021

Nissui Pharmaceutical Co., Ltd.

Announcement:

Transition of distribution in Europe, Turkey and Africa

Nissui Pharmaceutical Co., Ltd. (Headquarters: Tokyo, Taito-ku, Representative Director, President and CEO: ONO, Tokuya) is pleased to announce that from the 1st of January 2022 our food safety product range; Compact Dry, EC Blue, Food Stamp and Dehydrated Culture Media, will be supplied directly in Europe, Turkey and Africa by our European subsidiary Nissui Pharma Solutions (NPS).

NPS will supply both national/international distributors and food processing companies with our full range of food safely products.

For enquiries in Europe, Turkey and Africa please contact:

Nissui Pharma Solutions

10, rue Mesnil 75116, Paris France Email: contact@nissui-ps.comhttps://nissui-ps.com/

For enquiries in the Americas, Asia/Oceania and the Middle East please contact: Nissui Pharmaceutical Co., Ltd.

20F Ueno-Frontier Tower, 3-24-6 Ueno Taito-ku Tokyo 110-8736 Japan Email: contact@nissui-pharm.jphttps://www.nissui-pharm.co.jp/english/

Blank below

- 1 -

NISSUI PHARMACEUTICAL Co., Ltd.

Attachments

Original document
Permalink

Disclaimer

Nissui Pharmaceutical Co. Ltd. published this content on 01 October 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 01 October 2021 02:01:02 UTC.

Latest news about Nissui Pharmaceutical Co., Ltd.

MiCAN Technologies Inc. announced that it has received ¥50 million in funding from Nissui Pharmaceutical Co., Ltd.	23-03-22	CI
Nissui Pharmaceutical Co., Ltd.(TSE:4550) dropped from S&P Global BMI Index	22-09-19	CI
Tranche Update on Nissui Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on May 31, 2022.	22-09-06	CI
Tranche Update on Nissui Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on May 31, 2022.	22-09-06	CI
Nissui Pharmaceutical Co., Ltd.'s Equity Buyback announced on May 31, 2022 has closed with 12,552,248 shares, representing 55.67% for ¥20,861.84	22-09-04	CI
Shimadzu Corporation completed the acquisition of 34.7% stake in Nissui Pharmaceutical Co., Ltd. for ¥13.3 billion.	22-07-27	CI
Nissui Pharmaceutical Co., Ltd. announces an Equity Buyback for 13,237,063 shares, representing 58.71% for ¥22,000 million.	22-05-31	CI
Shimadzu Corporation made an offer to acquire a 45.9% stake in Nissui Pharmaceutical Co., Ltd. for ¥17.6 billion.	22-05-30	CI
Nissui Pharmaceutical Co., Ltd. authorizes a Buyback Plan.	22-05-30	CI
Nissui Pharmaceutical Co., Ltd. cancelled the acquisition of 10% stake in Nihon Techno Service Co., Ltd. from Takashi Masaki.	21-03-26	CI
Zeria Pharmaceutical Co., Ltd. cancelled the agreement to acquire Nissui Pharm Medical Sales Co., Ltd. from Nissui Pharmaceutical Co., Ltd..	21-01-16	CI
Nissui Pharmaceutical Co., Ltd.(TSE:4550) added to S&P Global BMI Index	20-09-21	CI
Nissui Pharmaceutical Co., Ltd. agreed to acquire 10% stake in Nihon Techno Service Co., Ltd. from Takashi Masaki.	20-03-26	CI
Nihon Techno Service Co., Ltd. announced that it has received funding from Nissui Pharmaceutical Co., Ltd.	20-03-26	CI
Zeria Pharmaceutical Co., Ltd. entered into an agreement to acquire Nissui Pharm Medical Sales Co., Ltd. from Nissui Pharmaceutical Co., Ltd. for ¥3.3 billion.	20-01-16	CI
MiCAN Technologies Inc. announced that it has received ¥21.6 million in funding from Nissui Pharmaceutical Co., Ltd.	19-10-30	CI
MiCAN Technologies Inc. announced that it expects to receive ¥21.6 million in funding from Nissui Pharmaceutical Co., Ltd.	19-10-29	CI
Nissui Pharmaceutical Co., Ltd. Announces Consolidated Earnings Results for the First Quarter Ended June 30, 2019; Provides Earnings Forecast for the Six Months Ended Ending September 30, 2019; Provides Dividend Forecast for the Second Quarter of Fiscal Year Ending March 31, 2020; Provides Dividend Forecast for Fiscal Year Ending March 31, 2020	19-07-29	CI
Nissui Pharmaceutical Co., Ltd. Announces Consolidated Earnings Results for the Nine Months Ended December 31, 2018; Provides Earnings Guidance for the Year Ending March 31, 2019	19-01-29	CI
Kola-Gen Pharma Co., Ltd. announced that it has received funding from Nissui Pharmaceutical Co., Ltd.	18-12-30	CI
Yoshimura Food Holdings K.K. cancelled the acquisition of Nissui Pharma Medical Sales Co., Ltd from Nissui Pharmaceutical Co., Ltd..	18-10-29	CI
Nissui Pharmaceutical Co., Ltd.(TSE:4550) dropped from S&P Global BMI Index	18-09-24	CI
Nissui Pharmaceutical Launches Global Colony Counter Service	18-08-30	CI
Yoshimura Food Holdings K.K. signed a basic agreement to acquire Nissui Pharma Medical Sales Co., Ltd from Nissui Pharmaceutical Co., Ltd..	18-08-06	CI
CellGenTech, Inc. announced that it expects to receive funding from Nissui Pharmaceutical Co., Ltd. and other investors	18-05-17	CI

Chart Nissui Pharmaceutical Co., Ltd.

Duration

Period

More charts

Company Profile

Nissui Pharmaceutical Co.,Ltd. is a Japan-based company mainly engaged in the manufacture, purchase and sale of clinical diagnostic drugs, industrial diagnostic drugs, pharmaceuticals, among others. The Company operates through two business segments. The Diagnostic Drug segment is involved in the manufacture, purchase and sale of culture media, clinical diagnostic drugs, industrial diagnostic drugs and raw materials for medical institutions, research institutions and industrial facilities, as well as the purchase and sale of testing equipment and other equipment. The Pharmaceutical segment is involved in the manufacture, purchase and sale of pharmaceuticals and health foods for pharmacies and drugstores. The Company's main products include clinical diagnostic drugs, industrial diagnostic drugs such as compactdry, pharmaceuticals such as therapeutics, nourishing tonics and health foods.

Sector

More about the company